This is the most harmful myth
Brand-name Mounjaro and Zepbound carry substantial list prices, though manufacturer coupons and insurance coverage can reduce out-of-pocket costs considerably
69,1 mmol/mol) or very high cardiovascular risk, and the regimen should include an SGLT-2 inhibitor and/or a GLP-1 receptor agonist ( 1c 1.52.0% above target, especially when therapies with high glycemic efficacy and proven cardiovascular or renal benefit are indicated ( 1c (11.6%, 102.6 mmol/mol), BMI 32.6 kg/m 2 , hypertension, proteinuria, fulfilling criteria for early combination therapy under both sets of guidelines
Product listings are supported by Certificates of Analysis tied to specific production lots rather than generic manufacturer documentation
Those are two different problems, and they have different solutions